Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

May CTC technologies promote better cancer management

M. Pesta, V. Kulda, A. Narsanska, J. Fichtl, O. Topolcan,

. 2015 ; 6 (1) : 1.

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc15014695

Grant support
NT14332 MZ0 CEP Register

In the case of cancer, death is usually not due to the primary tumor itself but due to dissemination. Analysis of the circulating tumor cells (CTCs), i.e., cells responsible for a formation of metastases, should provide information useful for the management of cancer patients, fulfilling the objectives of predictive, preventive, and personalized medicine (PPPM). Despite promising results, the decisions on stage of disease and how to guide the adjuvant treatment still do not include results of CTC assessment. We want to describe two major reasons why the recent diagnostic value of CTC analysis is not sufficient for clinical use. The first reason arises from the biological nature of the tumor itself and the second reason is associated with an interdisciplinary status of CTC diagnostics in the sense that it is neither a theme purely for pathologists nor for haemato-oncologists nor clinical biochemists. We anticipate that there are at least three areas where CTCs can be useful for clinical practice. The first is monitoring of treatment efficacy of cancer patients. The second is a molecular characterization of captured CTCs for targeted treatment, and the third is a cultivation of captured CTCs for drug sensitivity testing. All of these approaches allow researchers recognize and respond to changes of phenotype of cancer cells during disease progression and introduce PPPM into clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014695
003      
CZ-PrNML
005      
20190711112831.0
007      
ta
008      
150420s2015 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13167-014-0023-x $2 doi
035    __
$a (PubMed)25628770
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Pešta, Martin, $u Department of Biology, The Faculty of Medicine in Pilsen, Charles University in Prague, Karlovarska 48, 301 66 Pilsen, Czech Republic ; Biomedical Center, The Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $d 1976- $7 xx0073915
245    10
$a May CTC technologies promote better cancer management / $c M. Pesta, V. Kulda, A. Narsanska, J. Fichtl, O. Topolcan,
520    9_
$a In the case of cancer, death is usually not due to the primary tumor itself but due to dissemination. Analysis of the circulating tumor cells (CTCs), i.e., cells responsible for a formation of metastases, should provide information useful for the management of cancer patients, fulfilling the objectives of predictive, preventive, and personalized medicine (PPPM). Despite promising results, the decisions on stage of disease and how to guide the adjuvant treatment still do not include results of CTC assessment. We want to describe two major reasons why the recent diagnostic value of CTC analysis is not sufficient for clinical use. The first reason arises from the biological nature of the tumor itself and the second reason is associated with an interdisciplinary status of CTC diagnostics in the sense that it is neither a theme purely for pathologists nor for haemato-oncologists nor clinical biochemists. We anticipate that there are at least three areas where CTCs can be useful for clinical practice. The first is monitoring of treatment efficacy of cancer patients. The second is a molecular characterization of captured CTCs for targeted treatment, and the third is a cultivation of captured CTCs for drug sensitivity testing. All of these approaches allow researchers recognize and respond to changes of phenotype of cancer cells during disease progression and introduce PPPM into clinical practice.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kulda, Vlastimil, $u Department of Biochemistry, The Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $d 1979- $7 xx0138688
700    1_
$a Ňaršanská, Andrea, $u Department of Surgery, The Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $d 1984- $7 xx0209869
700    1_
$a Fichtl, Jakub $u Department of Surgery, The Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $7 xx0228675
700    1_
$a Topolčan, Ondřej, $u Department of Internal Medicine II, The Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $d 1943- $7 jn20000402383
773    0_
$w MED00181668 $t The EPMA journal $x 1878-5077 $g Roč. 6, č. 1 (2015), s. 1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25628770 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20190711113032 $b ABA008
999    __
$a ind $b bmc $g 1072276 $s 897573
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c 1 $d 1 $i 1878-5077 $m The EPMA journal $n EPMA J $x MED00181668
GRA    __
$a NT14332 $p MZ0
LZP    __
$a Pubmed-20150420

Find record

Citation metrics

Archiving options